MEP11508A - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof - Google Patents

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Info

Publication number
MEP11508A
MEP11508A MEP-115/08A MEP11508A MEP11508A ME P11508 A MEP11508 A ME P11508A ME P11508 A MEP11508 A ME P11508A ME P11508 A MEP11508 A ME P11508A
Authority
ME
Montenegro
Prior art keywords
group
preparation
alkoxy
therapeutic use
halogen atom
Prior art date
Application number
MEP-115/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Francoise Bono
Michael Bosch
Santos Victor Dos
Jean Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP11508A publication Critical patent/MEP11508A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MEP-115/08A 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof MEP11508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MEP11508A true MEP11508A (en) 2010-06-10

Family

ID=29724874

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-115/08A MEP11508A (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Country Status (29)

Country Link
US (2) US7294628B2 (de)
EP (2) EP1513836B1 (de)
JP (2) JP4441401B2 (de)
KR (1) KR100970812B1 (de)
CN (1) CN100448875C (de)
AR (2) AR040247A1 (de)
AT (2) ATE325122T1 (de)
AU (2) AU2003255645A1 (de)
BR (1) BR0311828A (de)
CA (1) CA2487840C (de)
CY (2) CY1107330T1 (de)
DE (2) DE60307632T2 (de)
DK (2) DK1513835T3 (de)
EA (1) EA007501B1 (de)
ES (2) ES2264001T3 (de)
HR (1) HRP20041157B1 (de)
IS (1) IS2302B (de)
MA (1) MA27233A1 (de)
ME (1) MEP11508A (de)
MX (1) MXPA04012341A (de)
NO (1) NO329669B1 (de)
NZ (1) NZ537044A (de)
PL (1) PL208711B1 (de)
PT (2) PT1513836E (de)
RS (2) RS52588B (de)
TW (2) TWI319400B (de)
UA (1) UA77526C2 (de)
WO (2) WO2003104225A1 (de)
ZA (1) ZA200409823B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
CN1984910A (zh) * 2004-07-16 2007-06-20 詹森药业有限公司 适用于神经变性疾病治疗的哌啶、哌嗪或者吗啉或它们的7元类似物的二聚化合物
EP2289510A1 (de) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten
EP1871420A4 (de) 2005-04-15 2010-09-22 Univ North Carolina Verfahren zur ermöglichung des überlebens von zellen über neurotrophin-mimetika
CL2008000725A1 (es) * 2007-03-15 2008-11-14 Schering Corp Compuestos derivados de heterociclos aromaticos; composicion farmaceutica; kit farmceuticos; uso de la composicion y de los compuestos como inhibidores de glucano sintasa para el tratamiento o prevencion del crecimiento de patogenos fungicos en planta y para tratar o prevenir infecciones producidas por hongos.
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ,インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
CN102740856B (zh) 2009-11-12 2015-02-18 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
AU2010333338A1 (en) 2009-12-14 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
EP2606894A1 (de) 2011-12-20 2013-06-26 Sanofi Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
IL281438B2 (en) 2018-09-18 2023-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
MX2021012310A (es) 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
EP3858439A1 (de) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amidderivate mit multimodaler aktivität gegen schmerzen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206109B (en) * 1987-10-26 1992-08-28 Pfizer Process for producing heterocyclic carbonylpropyl pyrimidinyl piperazine derivatives and pharmaceutical compositions comprising same
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
KR20050008802A (ko) 2005-01-21
PL208711B1 (pl) 2011-05-31
ATE325122T1 (de) 2006-06-15
UA77526C2 (en) 2006-12-15
KR100970812B1 (ko) 2010-07-16
HRP20041157B1 (en) 2012-11-30
NO20045331L (no) 2005-03-07
EP1513835B1 (de) 2006-08-16
WO2003104225A1 (fr) 2003-12-18
PT1513836E (pt) 2006-09-29
CA2487840A1 (en) 2003-12-18
MA27233A1 (fr) 2005-02-01
EP1513836B1 (de) 2006-05-03
US20050176722A1 (en) 2005-08-11
AU2003255644A1 (en) 2003-12-22
AR040247A1 (es) 2005-03-23
IS2302B (is) 2007-10-15
JP4437075B2 (ja) 2010-03-24
RS20050014A (sr) 2007-06-04
BR0311828A (pt) 2005-03-29
US20060167007A1 (en) 2006-07-27
US7468368B2 (en) 2008-12-23
ES2264001T3 (es) 2006-12-16
JP2005533051A (ja) 2005-11-04
TWI283671B (en) 2007-07-11
IS7579A (is) 2004-12-02
JP4441401B2 (ja) 2010-03-31
AU2003255645A1 (en) 2003-12-22
MXPA04012341A (es) 2005-09-30
ES2271637T3 (es) 2007-04-16
ATE336491T1 (de) 2006-09-15
PL374729A1 (en) 2005-10-31
NO329669B1 (no) 2010-11-29
AU2003255644B2 (en) 2009-02-05
CA2487840C (en) 2011-05-17
CY1107330T1 (el) 2012-11-21
ZA200409823B (en) 2006-07-26
TWI319400B (en) 2010-01-11
DK1513836T3 (da) 2006-09-11
EP1513836A1 (de) 2005-03-16
CY1105784T1 (el) 2011-02-02
DE60307632T2 (de) 2007-08-09
JP2005534661A (ja) 2005-11-17
EA007501B1 (ru) 2006-10-27
DE60305037T2 (de) 2006-12-14
CN100448875C (zh) 2009-01-07
HRP20041157A2 (en) 2005-06-30
CN1675203A (zh) 2005-09-28
NZ537044A (en) 2006-08-31
EP1513835A1 (de) 2005-03-16
US7294628B2 (en) 2007-11-13
HK1076110A1 (zh) 2006-01-06
EA200401470A1 (ru) 2005-06-30
TW200407321A (en) 2004-05-16
AR040246A1 (es) 2005-03-23
TW200400185A (en) 2004-01-01
DK1513835T3 (da) 2006-12-27
PT1513835E (pt) 2006-12-29
RS52588B (sr) 2013-04-30
DE60305037D1 (de) 2006-06-08
DE60307632D1 (de) 2006-09-28
WO2003104226A1 (fr) 2003-12-18

Similar Documents

Publication Publication Date Title
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
EA200401470A1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
HRP20080429T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
SE0302232D0 (sv) Novel Compounds
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
ATE503746T1 (de) Neue imidazolidinderivate
AU2006232435A8 (en) BCRP/ABCG2 inhibitor
DE60336735D1 (de) Neue biologischaktive molekü le
MY137964A (en) Benzofuran derivative
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
UA97837C2 (ru) Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
MY139258A (en) Carbamoyl-type benzofuran derivatives
DE602004009306D1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
TNSN06337A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
AR057748A1 (es) Derivados de 2,3 dihidroindol. composiciones farmaceuticas